Health20:43 · 1h ago

Hadassah Medical Center Recognized as International Training Hub for Gynecologic Oncology by ESGO

Behadrei HaredimReligious
Translated & summarized from Behadrei Haredim by baba
The story · English

Hadassah Medical Center in Jerusalem has achieved a significant international milestone as its Gynecologic Oncology Department received official accreditation from ESGO, the European Society of Gynaecological Oncology, as a recognized center for advanced fellowship training. This prestigious recognition is awarded to a limited number of medical centers worldwide after meeting stringent professional standards.

Professor Tamar Perry, head of the department, emphasized the broad significance of the accreditation, highlighting that it reflects the professional, academic, and human quality of their team. The accreditation process thoroughly evaluated all aspects of the department’s operations, from patient care quality to training future specialists.

Gynecologic oncology is a complex and sensitive medical field requiring extensive expertise, clinical experience, and multidisciplinary collaboration. Hadassah’s department serves as a leading national center, providing care to women across Israel while engaging in extensive research, including participation in international studies and the development of innovative treatments.

The ESGO recognition enables physicians from Israel and abroad to undergo advanced training at Hadassah, exposing them to complex cases, innovative therapies, multidisciplinary teamwork, and high-level research. Professor Perry noted that training the next generation of specialists is integral to their mission, ensuring continued excellence in patient care.

Hadassah regards this accreditation as a national achievement and an international endorsement of Israel’s medical, research, and training standards. Professor Perry concluded by attributing the success to hard work, deep commitment to patients, and teamwork, with the ultimate goal of providing the best possible care to women facing complex oncologic conditions while advancing the field globally.

Read the original at Behadrei Haredim
Open the live terminal